Dec 4 (Reuters) - Sanofi:
* European Medicines Agency says in emailed statement Sanofi’s dengue vaccine is currently being reviewed for a central marketing authorisation by the Agency’s Committee for Medicinal Products for Human Use (CHMP)
* EMA says any emerging data will be taken into account during assessment of Dengvaxia Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.